Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations

We studied the activity of a range of weakly basic and moderately lipophilic drugs against SARS CoV2 in Vero E6 cells, using Vero E6 survival, qPCR of viral genome and plaque forming assays. No clear relationship between their weakly basic and hydrophobic nature upon their activity was observed. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradfute, Steven B, Ye, Chunyan, Clarke, Elizabeth C, Kumar, Suresh, Timmins, Graham S, Deretic, Vojo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430564/
https://www.ncbi.nlm.nih.gov/pubmed/32817934
http://dx.doi.org/10.1101/2020.08.11.245100
_version_ 1783571445156151296
author Bradfute, Steven B
Ye, Chunyan
Clarke, Elizabeth C
Kumar, Suresh
Timmins, Graham S
Deretic, Vojo
author_facet Bradfute, Steven B
Ye, Chunyan
Clarke, Elizabeth C
Kumar, Suresh
Timmins, Graham S
Deretic, Vojo
author_sort Bradfute, Steven B
collection PubMed
description We studied the activity of a range of weakly basic and moderately lipophilic drugs against SARS CoV2 in Vero E6 cells, using Vero E6 survival, qPCR of viral genome and plaque forming assays. No clear relationship between their weakly basic and hydrophobic nature upon their activity was observed. However, the approved drugs ambroxol and ciprofloxacin showed potent activity at concentrations that are clinically relevant and within their known safety profiles, and so may provide potentially useful agents for preclinical and clinical studies in COVID-19.
format Online
Article
Text
id pubmed-7430564
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-74305642020-08-18 Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations Bradfute, Steven B Ye, Chunyan Clarke, Elizabeth C Kumar, Suresh Timmins, Graham S Deretic, Vojo bioRxiv Article We studied the activity of a range of weakly basic and moderately lipophilic drugs against SARS CoV2 in Vero E6 cells, using Vero E6 survival, qPCR of viral genome and plaque forming assays. No clear relationship between their weakly basic and hydrophobic nature upon their activity was observed. However, the approved drugs ambroxol and ciprofloxacin showed potent activity at concentrations that are clinically relevant and within their known safety profiles, and so may provide potentially useful agents for preclinical and clinical studies in COVID-19. Cold Spring Harbor Laboratory 2020-08-11 /pmc/articles/PMC7430564/ /pubmed/32817934 http://dx.doi.org/10.1101/2020.08.11.245100 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/It is made available under a CC-BY-NC-ND 4.0 International license (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Article
Bradfute, Steven B
Ye, Chunyan
Clarke, Elizabeth C
Kumar, Suresh
Timmins, Graham S
Deretic, Vojo
Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
title Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
title_full Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
title_fullStr Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
title_full_unstemmed Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
title_short Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
title_sort ambroxol and ciprofloxacin show activity against sars-cov2 in vero e6 cells at clinically-relevant concentrations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430564/
https://www.ncbi.nlm.nih.gov/pubmed/32817934
http://dx.doi.org/10.1101/2020.08.11.245100
work_keys_str_mv AT bradfutestevenb ambroxolandciprofloxacinshowactivityagainstsarscov2inveroe6cellsatclinicallyrelevantconcentrations
AT yechunyan ambroxolandciprofloxacinshowactivityagainstsarscov2inveroe6cellsatclinicallyrelevantconcentrations
AT clarkeelizabethc ambroxolandciprofloxacinshowactivityagainstsarscov2inveroe6cellsatclinicallyrelevantconcentrations
AT kumarsuresh ambroxolandciprofloxacinshowactivityagainstsarscov2inveroe6cellsatclinicallyrelevantconcentrations
AT timminsgrahams ambroxolandciprofloxacinshowactivityagainstsarscov2inveroe6cellsatclinicallyrelevantconcentrations
AT dereticvojo ambroxolandciprofloxacinshowactivityagainstsarscov2inveroe6cellsatclinicallyrelevantconcentrations

Ejemplares similares